Biological skin regeneration using epigenetic targets

Fahad Hussain Mohammed; Franz Cemic; Jürgen Hemberger; Shibashish Giri

doi:10.1016/j.drudis.2023.103495

Biological skin regeneration using epigenetic targets

Drug Discov Today. 2023 Apr;28(4):103495. doi: 10.1016/j.drudis.2023.103495. Epub 2023 Jan 18.

Authors

Fahad Hussain Mohammed¹, Franz Cemic², Jürgen Hemberger², Shibashish Giri³

Affiliations

¹ Biomedical and Biotechnological Center (BBZ), University of Leipzig, Leipzig, Germany; Institute of Biochemical Engineering & Analysis, University of Applied Sciences, Giessen, Germany.
² Institute of Biochemical Engineering & Analysis, University of Applied Sciences, Giessen, Germany.
³ Centre for Biotechnology and Biomedicine, Department of Cell Techniques and Applied Stem Cell Biology, University of Leipzig, Deutscher Platz 5, D-04103 Leipzig, Germany. Electronic address: shibashishgermany@gmail.com.

PMID: 36681237
DOI: 10.1016/j.drudis.2023.103495

Abstract

Epigenetics targets are the newest branches for building a novel platform of drugs for preventive and regenerative skin health care. Epigenetic regions [vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), transforming growth factor beta (TGFβ), DNA methyltransferases (DNMTs), histone deacetylase 1/2 (HDAC1/2), and miRNA) are innovative druggable targets. As we discuss here, a series of epigenetic-based small molecules are undergoing both clinical and preclinical trials for skin regeneration. Epigenetic writers, eraser targets, and epigenetic readers will become the key therapeutic windows for skin regenerative in the near future.

Keywords: DNA methylation; DNMT; EGFR; HDAC; TGF-β; VEGF; epigenetics; miR.

Publication types

Review

MeSH terms

DNA Methylation
Epigenesis, Genetic
Histone Deacetylase Inhibitors* / pharmacology
Histone Deacetylase Inhibitors* / therapeutic use
Regeneration
Vascular Endothelial Growth Factor A*

Substances

Vascular Endothelial Growth Factor A
Histone Deacetylase Inhibitors